RSC-1255 Dose Expansion

Phase 1Small molecule

RSC-1255 Dose Expansion is one of 42 small molecule programs targeting Advanced Malignant Solid Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid NeoplasmRecruiting

Advanced Malignant Solid NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

43 competitors in Advanced Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Phase 3

2 2

Lynparza

AstraZeneca

Phase 2

4 3

Ibrance

Pfizer

Phase 2

4 4

Taxol

Teva

Phase 2

2 5

Koselugo

AstraZeneca

Phase 2

2 6

Mektovi

Pfizer

Phase 2

2 7

Retevmo

Eli Lilly

Phase 2

1 8

Keytruda

Merck & Co.

Phase 2

1 9

Talzenna

Pfizer

Phase 2

1 10

Balversa

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Malignant Solid Neoplasm

NCT04678648

Clinical

Trials by Indication[1]

Advanced Malignant Solid Neoplasm1 trial

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

Recruiting·RRasCal Therapeutics, Inc.·Phase 1·NCT04678648·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RSC-1255 Dose Expansion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RSC-1255 Dose Expansion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RSC-1255 Dose Expansion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RasCal Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRasCal Therapeutics, Inc.

RSC-1255 Dose Expansion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Advanced Malignant Solid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News